Navigation Links
Chindex International to Report Fiscal 2009 First Quarter Financial Results
Date:7/31/2008

BETHESDA, Md., July 31 /Xinhua-PRNewswire/ -- Chindex International, Inc. (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it intends to release its fiscal 2009 first quarter financial results on Thursday, August 14, 2008, before the market opens. Management will host a conference call at 8:00 am ET that day to discuss financial results.

To participate in the conference call, international callers dial 201-689-8565 and domestic callers dial 877-407-0778 approximately 10 minutes before the conference call is scheduled to begin.

The telephone replay will be available on the day of the call at (international) 201-612-7415 and (domestic) 877-660-6853, replay passcodes (both are required for playback) account # 286; passcode 292563; and continue to be available through August 25, 2008.

This call is also being webcast by http://www.investorcalendar.com/IC/CEPage.asp?ID=132391 and will be accessible at Chine's website http://ir.chindex.com/events.cfm. The event will be archived and available for replay through November 12, 2008.

Chindex is in the process of finalizing its financial statements for the fiscal 2009 first quarter and will file a Form 12b-25 to extend the due date of its Form 10-Q, which will be filed on or before August 19, 2008.

About Chindex International, Inc.

Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including H
'/>"/>

SOURCE Chindex International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Chindex International, Inc. Announces CDC Contract Signing
2. Chindexs United Family Healthcare Launches ChinaHealthWatch.org - A global resource for travelers to China
3. Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S
4. Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster
5. Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington
6. Chindex International, Inc. to Present at China Investment Conferences in New York City - May 20, 21, 22; Conferences Presented By Brean Murray, Carret & Co., Oppenhiemer & Co. and Citigroup
7. Chindex International Announces the Opening of Wuxi United Family Healthcare Center
8. Chindex International, Inc. Announces Three-For-Two Stock Split
9. Chindex International, Inc. Announces Results for the Quarter and Nine Months Ended December 31, 2007
10. Chindex International, Inc. Announces Transfer to NASDAQ Global Market
11. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...RNewswire/ -- BAPTIST HEALTH, a six-hospital,syst...gest health system, has,expanded its use of Clini...,solution that enabled the system,s pharmacists to...ve more than $1 million. , "Data we collect...hat,CareFocus prompts approximately half of the p...
(Date:12/4/2008)...se seen with standard dose of daunorubicin, study ...ws) -- A high dose of the chemotherapy drug daunor...usly untreated acute myeloid leukemia (AML), preli...tional Cancer Institute (NCI) show. , AML is a ...cluded 633 patients, aged 16 to 60, who were rando...
(Date:12/4/2008)...s Leaders of Virginia, Maryland and D.C. AIDS Offi...wswire/ -- Nationally, Washington, D.C. ranks firs...C., 82 percent are African American. In an effort...the South, today,s Living Quilt roundtable at the ...e leaders of the Virginia, Maryland and District o...
(Date:12/4/2008)...his December, and on the eve of its 35th Anniversa...unch an integrated Season of Giving marketing camp... long way. The initiative, designed to drive perso...harity and its three core programs: Ronald McDonal...d McDonald Care Mobile. , ...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3
...gs from a recent study researchers say, the ancien...cal application. Lymphoma patients// who took part...n those in a control group. The study was conducte...ther undergoing treatment or who had concluded tre...
...extended exposure to sunlight may lead to age-rela...egeneration an eye // disorder that can cause blin...ts for five years and more than 2,700 patients for...86 years old. Participants who reported being in t...
...s( DVT ) is a blood clot that develops deep in the...lung. // People who require prolonged bed rest ar... blood circulation ,especially patients in intensi...a serious risk for DVT. Recent studies have shown ...
...w individuals in lower socioeconomic groups, as me...ul days than those with // higher socioeconomic st...rger impact on their health. While those with more...y are not as affected by it. For the study, more t...
Other Medicine News:
(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products: